Published in J Virol on May 01, 1996
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol (1999) 2.24
Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol (1997) 2.08
Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol (1997) 1.75
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptor. Proc Natl Acad Sci U S A (1998) 1.58
Characterization of Nef-CXCR4 interactions important for apoptosis induction. J Virol (2004) 1.24
Rationally designed peptide regulators of protein kinase C. Trends Endocrinol Metab (2008) 1.17
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J Med Chem (2011) 0.98
Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog (2011) 0.97
Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions. J Virol (1999) 0.96
Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol (1997) 0.95
Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases. Exp Biol Med (Maywood) (2011) 0.89
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res Ther (2006) 0.84
Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem (2014) 0.77
Peptidomimetics as a new generation of antimicrobial agents: current progress. Infect Drug Resist (2014) 0.76
Development of an enzyme-linked immunosorbent assay for measurement of serum-associated ALX40-4C. Clin Diagn Lab Immunol (1997) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science (1985) 12.75
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell (1985) 11.28
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III. Science (1985) 10.36
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature (1991) 6.79
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (1992) 3.79
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Identification of the residues in human CD4 critical for the binding of HIV. Cell (1989) 3.71
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1988) 2.82
A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell (1990) 2.63
Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol (1991) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retroviruses (1993) 2.39
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev (1991) 2.34
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science (1993) 1.97
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology (1992) 1.84
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood (1995) 1.62
Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J Virol (1994) 1.55
The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem (1992) 1.54
Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retroviruses (1992) 1.45
CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle. Proc Natl Acad Sci U S A (1989) 1.30
Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J Virol (1994) 1.27
HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J (1993) 1.19
Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J Leukoc Biol (1994) 1.09
Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein. J Virol (1995) 1.08
Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS (1994) 1.06
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J Virol (1995) 1.02
Functional characterization of Tat protein from human immunodeficiency virus. Evidence that Tat links viral RNAs to nuclear matrix. J Biol Chem (1990) 0.92
Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. Drugs Exp Clin Res (1995) 0.89
CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol Immunol (1993) 0.84
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A (1985) 4.28
Clearance of HIV infection in a perinatally infected infant. N Engl J Med (1995) 3.76
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature (1990) 3.28
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science (1988) 3.22
Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev (1991) 3.06
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67
Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II. Proc Natl Acad Sci U S A (1984) 2.67
Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning. J Virol (1981) 2.49
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
The x gene is essential for HTLV replication. Science (1985) 2.44
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42
Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc Natl Acad Sci U S A (1983) 2.41
Long terminal repeats of human T-cell leukaemia virus II genome determine target cell specificity. Nature (1984) 2.39
HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. Science (1988) 2.37
Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature (1983) 2.36
Rapid construction of large synthetic genes: total chemical synthesis of two different versions of the bovine prochymosin gene. Gene (1987) 2.36
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut (2007) 2.28
Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum (2001) 2.27
Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection. J Virol (1982) 2.26
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 2.15
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod (1994) 2.12
Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol (2001) 2.11
Nucleotide sequence of the 3' region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A (1984) 2.10
Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08
Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis. N Engl J Med (2001) 2.04
Accuracy of in vivo aminoacylation requires proper balance of tRNA and aminoacyl-tRNA synthetase. Science (1988) 1.87
Functional relation between HTLV-II x and adenovirus E1A proteins in transcriptional activation. Science (1985) 1.87
Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science (1998) 1.83
HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr (1991) 1.72
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med (1997) 1.70
Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nat Struct Biol (1998) 1.69
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Substitution of 5' helper virus sequences into non-rel portion of reticuloendotheliosis virus strain T suppresses transformation of chicken spleen cells. Cell (1982) 1.69
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J (1991) 1.66
Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science (1985) 1.65
Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A (1991) 1.62
Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood (1995) 1.62
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
Regulation of AIDS virus expression. Cell (1986) 1.57
Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol (2000) 1.55
Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A (1999) 1.52
Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J Virol (1997) 1.52
Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol (1992) 1.52
Antibody-directed targeting of retroviral vectors via cell surface antigens. J Virol (2001) 1.50
Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol (1990) 1.48
HTLV x-gene product: requirement for the env methionine initiation codon. Science (1985) 1.45
Expression of the 3' terminal region of human T-cell leukemia viruses. Science (1984) 1.44
A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med (1986) 1.44
Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for Tat binding and trans activation: model for TAR RNA tertiary structure. J Virol (1992) 1.43
HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science (1988) 1.41
Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med (1997) 1.41
Characterization of a novel HTLV-infected cell line. Blood (1984) 1.40
Structure and expression of c-rel, the cellular homolog to the oncogene of reticuloendotheliosis virus strain T. J Virol (1983) 1.40
Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol (1997) 1.37
Regulation of human T cell leukemia virus expression. FASEB J (1990) 1.36
Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res (1989) 1.36
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33
The number of positively charged amino acids in the basic domain of Tat is critical for trans-activation and complex formation with TAR RNA. Proc Natl Acad Sci U S A (1991) 1.32
Human T-cell leukemia virus type II nucleotide sequences between env and the last exon of tax/rex are not required for viral replication or cellular transformation. J Virol (1995) 1.32
A new reporter system for detection of retroviral infection. Gene Ther (1995) 1.32
Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol (1992) 1.32
Analysis of the inducible MEL1 gene of Saccharomyces carlsbergensis and its secreted product, alpha-galactosidase (melibiase). Gene (1985) 1.31
Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol (2001) 1.30
Human immunodeficiency virus causes mononuclear phagocyte dysfunction. Proc Natl Acad Sci U S A (1990) 1.26
Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus envelope. J Virol (2001) 1.22
Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene (1989) 1.22
Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A (1999) 1.22
Use of multiple molecular subtyping techniques to investigate a Legionnaires' disease outbreak due to identical strains at two tourist lodges. J Clin Microbiol (1993) 1.21
Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. J Virol (1995) 1.21